fight-202: pemigatinib in cca
Published 3 years ago • 166 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
2:40
fight-202: pemigatinib for fgfr2 altered cca
-
3:30
final results from fight-202: pemigatinib for patients with fgfr-mutated advanced cholangiocarcinoma
-
2:14
fight-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma
-
2:40
the rapid growth of fgfr2 inhibitors: pemigatinib in fight-202
-
2:15
impact of prior systemic therapy on pfs patients enrolled in fight-202
-
6:31
understanding cholangiocarcinoma
-
![[complex pci 2023] live case 4: cto](https://i.ytimg.com/vi/fKy3ZptLPDg/mqdefault.jpg)
49:11
[complex pci 2023] live case 4: cto
-
1:04:18
ccf webinar: cholangiocarcinoma 101
-
4:51
natural history of patients with advanced cca with fgfr2 gene alterations or wild-type fgfr2
-
15:08
ac22 - komodo updates
-
5:26
fight update: 1l bemarituzumab in fgfr2b gastric cancer
-
11:05
ac22 - clonal origins of metastatic cholangiocarcinoma
-
2:31
efficacy of second-line chemotherapy in advanced cca with fgfr2 fusions
-
2:01
fgfr mutations
-
2:58
tislelizumab in patients with unresectable hcc demonstrates durable responses
-
4:03
fgfr inhibitors for cca & bladder cancer
-
3:29
fda approved pemigatinib new drug for cholangiocarcinoma, $18, 448 for 14 days, but i'm 2 die 2
-
1:51
fgfr inhibitors
-
4:12
fgfr2 inhibitors in advanced cholangiocarcinoma
-
1:00:01
webinar: targeting the fgfr pathway: infigratinib in cholangiocarcinoma
-
10:39
ac22 - explore signaling pathways and combination therapy in fgfr2-activated cholangiocarcinoma
-
35:30
ac22 - cholangiocarcinoma updates panel discussion